Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Negrar di Valpolicella – page 5

71 clinical trials in Negrar di Valpolicella, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Negrar di Valpolicella at a glance
71
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

71 trials in Negrar di Valpolicella

Open in trial search

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Crohn's disease

Not recruiting

Study on the Safety and Effects of ORG-129 in Patients with Fibrostenotic Crohn's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.U.

Lung disorder

Not recruiting

Study on the Effectiveness of Osimertinib for Patients with EGFR Mutant Non-Small Cell Lung Cancer Based on TP53 Mutation Status

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Universita Degli Studi Di Padova

Crohn's disease

Not recruiting

Study on BI 706321 and Ustekinumab for Patients with Moderate to Severe Crohn's Disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 706321
  • Sponsor:Boehringer Ingelheim International GmbH

Study on Radium-223, Docetaxel, and Prednisone for Patients with Bone-Only Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab for Patients with Fistulizing Perianal Crohn's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Crohn's disease

Not recruiting

Study on the Effects of Etrasimod Arginine for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Etrasimod Arginine
  • Sponsor:Arena Pharmaceuticals Inc.

Breast cancer

Not recruiting

Study on Trastuzumab Deruxtecan and Drug Combination for Patients with High-Risk HER2-Positive Early Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB

Study of Pembrolizumab for Patients with Recurrent, Platinum-Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Study on the Effects of RGX-314 Gene Therapy Compared to Aflibercept and Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Negrar di Valpolicella

What the registry says about research in the country

01 Oncology

Clinical research in Negrar di Valpolicella is strongly focused on breast cancer, prostate cancer, lung cancer, and other advanced solid tumors, with studies spanning both early and metastatic disease.

  • Testing new treatment strategies for HER2-positive and ER-positive breast cancer
  • Evaluating therapies for prostate cancer, including high-risk and metastatic forms
  • Studying treatment options for non-small cell lung cancer and pancreatic cancer
  • Exploring improved cancer control, relapse prevention, and survival outcomes

These trials aim to refine cancer care by comparing new approaches with standard treatments and identifying more effective options for patients.

02 Gastroenterology and Digestive Diseases

A major area of research centers on inflammatory bowel disease, especially Crohn’s disease and ulcerative colitis, alongside related digestive conditions.

  • Investigating therapies for moderately to severely active Crohn’s disease
  • Studying treatment approaches for ulcerative colitis
  • Addressing difficult subtypes such as fibrostenotic and fistulizing Crohn’s disease
  • Assessing maintenance of remission and long-term disease control

Many of these studies focus on easing symptoms, improving endoscopic outcomes, and helping patients achieve more durable remission.

03 Ophthalmology

Eye research in this city includes studies on age-related macular degeneration, especially neovascular AMD and geographic atrophy.

  • Testing new therapies for wet age-related macular degeneration
  • Evaluating options for atrophic age-related macular degeneration
  • Studying vision-preserving approaches and treatment durability
  • Exploring improved delivery systems for ocular therapy

The goal is to preserve sight, slow disease progression, and improve convenience for people living with chronic retinal disease.

04 Urology and Genitourinary Oncology

Several trials examine prostate cancer across localized, oligometastatic, and castration-resistant stages, reflecting a broad interest in genitourinary cancer care.

  • Studying treatment for high-risk localized prostate cancer
  • Assessing care for oligometastatic and metastatic castration-resistant disease
  • Using advanced imaging to improve detection of spread
  • Evaluating ways to delay progression and improve quality of life

These studies are designed to support earlier intervention and more precise treatment selection for patients with prostate cancer.

05 Breast Cancer Research

Breast cancer remains one of the most active fields of investigation, with trials covering early-stage, locally advanced, and metastatic breast cancer.

  • Testing therapies for HER2-positive, HER2-low, and HER2-negative disease
  • Studying ESR1-mutated and node-positive breast cancer
  • Exploring adjuvant and neoadjuvant treatment strategies
  • Aiming to improve response rates and reduce recurrence risk

Research in this area is centered on finding more personalized approaches that can better match treatment to tumor biology.

06 Respiratory Diseases and Lung Cancer

Trials in respiratory medicine focus mainly on non-small cell lung cancer, including advanced and recurrent disease, with some work also touching on infection-related respiratory conditions.

  • Evaluating new options for advanced non-small cell lung cancer
  • Studying treatments for recurrent or metastatic lung cancer
  • Exploring targeted and immune-based approaches
  • Supporting better disease control in hard-to-treat cases

This research aims to improve outcomes where current treatments may not be enough on their own.

07 Immunology and Autoimmune Diseases

Another important area involves immune-mediated diseases, especially inflammatory bowel disease and related immune system disorders.

  • Studying immune-targeted therapies for Crohn’s disease and ulcerative colitis
  • Examining inflammation control and mucosal healing
  • Assessing long-term safety of immune-modulating treatments
  • Looking at ways to maintain remission over time

These trials are aimed at improving symptom control while reducing the burden of chronic immune-related disease.

08 Cardiovascular and Stroke Prevention

Research in cardiovascular disease includes studies aimed at preventing recurrent events after ischemic stroke or transient ischemic attack.

  • Testing new approaches to reduce stroke recurrence
  • Evaluating balance between clot prevention and bleeding risk
  • Supporting secondary prevention after acute vascular events

These trials are focused on safer, more effective ways to protect patients at high risk of another cerebrovascular event.

09 Diagnostic Imaging and Investigative Techniques

Several studies in Negrar di Valpolicella use advanced diagnostic techniques to improve disease detection, staging, and treatment monitoring.

  • Assessing imaging tools for prostate cancer and metastatic spread
  • Studying methods that better identify response to therapy
  • Supporting more accurate diagnosis in oncology and eye disease
  • Helping guide treatment decisions with more reliable data

These projects reflect a strong interest in precision diagnostics and in tools that can make clinical care more tailored and timely.

10 Virus Diseases and Vaccination

Some trials address virus diseases, including studies related to respiratory syncytial virus, with a focus on immune protection in older adults.

  • Evaluating the immune response to RSV vaccination
  • Studying protection in adults aged 60 and older
  • Looking at vaccine safety and sustained immune benefit

These studies aim to strengthen prevention against seasonal respiratory infection in vulnerable populations.

11 Other Digestive and Metabolic Conditions

Additional research includes cholestatic and other digestive-related conditions, broadening the city’s profile beyond the main cancer and bowel disease programs.

  • Studying symptoms linked to cholestasis and related liver-bile disorders
  • Exploring ways to improve comfort and disease management
  • Supporting longer-term treatment tolerability

These trials add to a diverse research environment that combines common chronic diseases with more specialized clinical questions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.